Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors

Guolin Zhang, Hannah Scarborough, Jihye Kim, Andrii I. Rozhok, Yian Ann Chen, Xiaohui Zhang, Lanxi Song, Yun Bai, Bin Fang, Richard Z. Liu, John Koomen, Aik-Choon Tan, James Degregori, Eric B. Haura

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Patients with lung cancers harboring anaplastic lymphoma kinase (ALK) gene fusions benefit from treatment with ALK inhibitors, but acquired resistance inevitably arises. A better understanding of proximal ALK signaling mechanisms may identify sensitizers to ALK inhibitors that disrupt the balance between prosurvival and proapoptotic effector signals. Using affinity purification coupled with mass spectrometry in an ALK fusion lung cancer cell line (H3122), we generated an ALK signaling network and investigated signaling activity using tyrosine phosphoproteomics. We identified a network of 464 proteins composed of subnetworks with differential response to ALK inhibitors. A small hairpin RNA screen targeting 407 proteins in this network revealed 64 and 9 proteins that when knocked down sensitized cells to crizotinib and alectinib, respectively. Among these, knocking down fibroblast growth factor receptor substrate 2 (FRS2) or coiled-coil and C2 domain-containing protein 1A (CC2D1A), both scaffolding proteins, sensitized multiple ALK fusion cell lines to the ALK inhibitors crizotinib and alectinib. Collectively, our data set provides a resource that enhances our understanding of signaling and drug resistance networks consequent to ALK fusions and identifies potential targets to improve the efficacy of ALK inhibitors in patients.

Original languageEnglish
Article numberrs12
JournalScience Signaling
Volume9
Issue number450
DOIs
Publication statusPublished - 2016 Oct 18
Externally publishedYes

Fingerprint

RNA Interference
RNA
Fusion reactions
Proteins
Lung Neoplasms
anaplastic lymphoma kinase
Receptor, Fibroblast Growth Factor, Type 2
Cells
Fibroblast Growth Factor Receptors
Cell Line
Gene Fusion
Protein Transport
Drug Resistance
Small Interfering RNA
Purification
Mass spectrometry
Tyrosine
Mass Spectrometry
Genes

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Zhang, G., Scarborough, H., Kim, J., Rozhok, A. I., Chen, Y. A., Zhang, X., ... Haura, E. B. (2016). Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors. Science Signaling, 9(450), [rs12]. https://doi.org/10.1126/scisignal.aaf5011

Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors. / Zhang, Guolin; Scarborough, Hannah; Kim, Jihye; Rozhok, Andrii I.; Chen, Yian Ann; Zhang, Xiaohui; Song, Lanxi; Bai, Yun; Fang, Bin; Liu, Richard Z.; Koomen, John; Tan, Aik-Choon; Degregori, James; Haura, Eric B.

In: Science Signaling, Vol. 9, No. 450, rs12, 18.10.2016.

Research output: Contribution to journalArticle

Zhang, G, Scarborough, H, Kim, J, Rozhok, AI, Chen, YA, Zhang, X, Song, L, Bai, Y, Fang, B, Liu, RZ, Koomen, J, Tan, A-C, Degregori, J & Haura, EB 2016, 'Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors', Science Signaling, vol. 9, no. 450, rs12. https://doi.org/10.1126/scisignal.aaf5011
Zhang, Guolin ; Scarborough, Hannah ; Kim, Jihye ; Rozhok, Andrii I. ; Chen, Yian Ann ; Zhang, Xiaohui ; Song, Lanxi ; Bai, Yun ; Fang, Bin ; Liu, Richard Z. ; Koomen, John ; Tan, Aik-Choon ; Degregori, James ; Haura, Eric B. / Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors. In: Science Signaling. 2016 ; Vol. 9, No. 450.
@article{f83e57a0a6eb4715b779da6bb6579bb4,
title = "Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors",
abstract = "Patients with lung cancers harboring anaplastic lymphoma kinase (ALK) gene fusions benefit from treatment with ALK inhibitors, but acquired resistance inevitably arises. A better understanding of proximal ALK signaling mechanisms may identify sensitizers to ALK inhibitors that disrupt the balance between prosurvival and proapoptotic effector signals. Using affinity purification coupled with mass spectrometry in an ALK fusion lung cancer cell line (H3122), we generated an ALK signaling network and investigated signaling activity using tyrosine phosphoproteomics. We identified a network of 464 proteins composed of subnetworks with differential response to ALK inhibitors. A small hairpin RNA screen targeting 407 proteins in this network revealed 64 and 9 proteins that when knocked down sensitized cells to crizotinib and alectinib, respectively. Among these, knocking down fibroblast growth factor receptor substrate 2 (FRS2) or coiled-coil and C2 domain-containing protein 1A (CC2D1A), both scaffolding proteins, sensitized multiple ALK fusion cell lines to the ALK inhibitors crizotinib and alectinib. Collectively, our data set provides a resource that enhances our understanding of signaling and drug resistance networks consequent to ALK fusions and identifies potential targets to improve the efficacy of ALK inhibitors in patients.",
author = "Guolin Zhang and Hannah Scarborough and Jihye Kim and Rozhok, {Andrii I.} and Chen, {Yian Ann} and Xiaohui Zhang and Lanxi Song and Yun Bai and Bin Fang and Liu, {Richard Z.} and John Koomen and Aik-Choon Tan and James Degregori and Haura, {Eric B.}",
year = "2016",
month = "10",
day = "18",
doi = "10.1126/scisignal.aaf5011",
language = "English",
volume = "9",
journal = "Science Signaling",
issn = "1937-9145",
publisher = "American Association for the Advancement of Science",
number = "450",

}

TY - JOUR

T1 - Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors

AU - Zhang, Guolin

AU - Scarborough, Hannah

AU - Kim, Jihye

AU - Rozhok, Andrii I.

AU - Chen, Yian Ann

AU - Zhang, Xiaohui

AU - Song, Lanxi

AU - Bai, Yun

AU - Fang, Bin

AU - Liu, Richard Z.

AU - Koomen, John

AU - Tan, Aik-Choon

AU - Degregori, James

AU - Haura, Eric B.

PY - 2016/10/18

Y1 - 2016/10/18

N2 - Patients with lung cancers harboring anaplastic lymphoma kinase (ALK) gene fusions benefit from treatment with ALK inhibitors, but acquired resistance inevitably arises. A better understanding of proximal ALK signaling mechanisms may identify sensitizers to ALK inhibitors that disrupt the balance between prosurvival and proapoptotic effector signals. Using affinity purification coupled with mass spectrometry in an ALK fusion lung cancer cell line (H3122), we generated an ALK signaling network and investigated signaling activity using tyrosine phosphoproteomics. We identified a network of 464 proteins composed of subnetworks with differential response to ALK inhibitors. A small hairpin RNA screen targeting 407 proteins in this network revealed 64 and 9 proteins that when knocked down sensitized cells to crizotinib and alectinib, respectively. Among these, knocking down fibroblast growth factor receptor substrate 2 (FRS2) or coiled-coil and C2 domain-containing protein 1A (CC2D1A), both scaffolding proteins, sensitized multiple ALK fusion cell lines to the ALK inhibitors crizotinib and alectinib. Collectively, our data set provides a resource that enhances our understanding of signaling and drug resistance networks consequent to ALK fusions and identifies potential targets to improve the efficacy of ALK inhibitors in patients.

AB - Patients with lung cancers harboring anaplastic lymphoma kinase (ALK) gene fusions benefit from treatment with ALK inhibitors, but acquired resistance inevitably arises. A better understanding of proximal ALK signaling mechanisms may identify sensitizers to ALK inhibitors that disrupt the balance between prosurvival and proapoptotic effector signals. Using affinity purification coupled with mass spectrometry in an ALK fusion lung cancer cell line (H3122), we generated an ALK signaling network and investigated signaling activity using tyrosine phosphoproteomics. We identified a network of 464 proteins composed of subnetworks with differential response to ALK inhibitors. A small hairpin RNA screen targeting 407 proteins in this network revealed 64 and 9 proteins that when knocked down sensitized cells to crizotinib and alectinib, respectively. Among these, knocking down fibroblast growth factor receptor substrate 2 (FRS2) or coiled-coil and C2 domain-containing protein 1A (CC2D1A), both scaffolding proteins, sensitized multiple ALK fusion cell lines to the ALK inhibitors crizotinib and alectinib. Collectively, our data set provides a resource that enhances our understanding of signaling and drug resistance networks consequent to ALK fusions and identifies potential targets to improve the efficacy of ALK inhibitors in patients.

UR - http://www.scopus.com/inward/record.url?scp=84991829690&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991829690&partnerID=8YFLogxK

U2 - 10.1126/scisignal.aaf5011

DO - 10.1126/scisignal.aaf5011

M3 - Article

VL - 9

JO - Science Signaling

JF - Science Signaling

SN - 1937-9145

IS - 450

M1 - rs12

ER -